CLDE 361
Alternative Names: CLDE-361Latest Information Update: 17 May 2024
At a glance
- Originator Clade Therapeutics
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Myasthenia gravis
Most Recent Events
- 24 Apr 2024 Early research in Myasthenia gravis in USA (Parenteral) prior to April 2024 (Century Therapeutics pipeline, April 2024)
- 11 Apr 2024 Clade Therapeutics has been acquired by Century Therapeutics